76 Doctors to UK Government: Don’t Make Same Mistake as FDA, ‘mRNA Vaccines Are Totally Inappropriate for Small Children’
- 76 Doctors to UK Government: Don’t Make Same Mistake as FDA, ‘mRNA Vaccines Are Totally Inappropriate for Small Children’
by Robert W. Malone M.D., M.S., https://childrenshealthdefense.org/defender/
In a letter to the Medical and Healthcare products Regulatory Agency and other U.K. government officials, 76 doctors explain why the recent U.S. Food and Drug Administration’s decision authorizing COVID vaccinations in infants and young children must not happen in the U.K.
–
The letter below was signed by 76 doctors in the U.K. and sent to the Medical and Healthcare products Regulatory Agency (MHRA), and other U.K. Government officials. This letter lays out comprehensive reasons why the recent U.S. Food and Drug Administration’s (FDA’s) decision authorizing COVID vaccinations in infants and young children must not happen in the U.K.
–
June 30, 2022
Dear Dr. Raine,
–
We are writing to you urgently concerning the announcement that the FDA has granted an Emergency Use Authorization for both Pfizer and Moderna COVID-19 vaccines in preschool children.
–
We would urge you to consider very carefully the move to vaccinate ever younger children against SARS-CoV-2, despite the gradual but significant reducing virulence of successive variants, the increasing evidence of rapidly waning vaccine efficacy, the increasing concerns over long-term vaccine harms, and the knowledge that the vast majority of this young age group have already been exposed to SARS-CoV-2 repeatedly and have demonstrably effective immunity.
–
Thus, the balance of benefit and risk which supported the rollout of mRNA vaccines to the elderly and vulnerable in 2021 is totally inappropriate for small children in 2022.
–
We also strongly challenge the addition of COVID-19 vaccination into the routine child immunization program despite no demonstrated clinical need, known and unknown risks (see below) and the fact that these vaccines still have only conditional marketing authorization.
–
It is noteworthy that the Pfizer documentation presented to the FDA has huge gaps in the evidence provided:- The protocol was changed mid-trial. The original two-dose schedule exhibited poor immunogenicity with efficacy far below the required standard. A third dose was added by which time many of the original placebo recipients had been vaccinated.
- There was no statistically significant difference between the placebo and vaccinated groups in either the 6-23-month age group or the 2-4-year-olds, even after the third dose. Astonishingly, the results were based on just three participants in the younger age group (one vaccinated and two placebo) and just seven participants in the older 2-4-year-olds (two vaccinated and five placebo). Indeed, for the younger age group the confidence intervals ranged from minus-367% to plus-99%. The manufacturer stated that the numbers were too low to draw any confident conclusions. Moreover, these limited numbers come only from children infected more than seven days after the third dose.
end